An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Eton Pharmaceuticals, Inc (Nasdaq: ETON) will present at the Citizens JMP Life Sciences Conference in New York on May 13, 2024. Sean Brynjelsen, CEO, and James Gruber, CFO, will participate. For meeting requests, contact Citizens JMP.
Eton Pharmaceuticals, Inc. (Nasdaq: ETON) parteciperà alla Citizens JMP Life Sciences Conference a New York il 13 maggio 2024. Sean Brynjelsen, CEO, e James Gruber, CFO, saranno presenti. Per richieste di incontri, contattare Citizens JMP.
Eton Pharmaceuticals, Inc. (Nasdaq: ETON) se presentará en la Conferencia de Life Sciences de Citizens JMP en Nueva York el 13 de mayo de 2024. Participarán Sean Brynjelsen, CEO, y James Gruber, CFO. Para solicitudes de reuniones, contacte a Citizens JMP.
이튼 파마슈티컬스, Inc (Nasdaq: ETON)은 2024년 5월 13일 뉴욕에서 열리는 시민즈 JMP 라이프 사이언스 컨퍼런스에 참가할 예정입니다. CEO인 숀 브린젤슨과 CFO인 제임스 그루버가 참여할 것입니다. 만남 요청은 시민즈 JMP에 연락하십시오.
Eton Pharmaceuticals, Inc. (Nasdaq : ETON) participera à la Conférence des Sciences de la Vie de Citizens JMP à New York le 13 mai 2024. Sean Brynjelsen, directeur général, et James Gruber, directeur financier, seront présents. Pour des demandes de rendez-vous, contactez Citizens JMP.
Eton Pharmaceuticals, Inc. (Nasdaq: ETON) wird am 13. Mai 2024 auf der Citizens JMP Life Sciences Konferenz in New York präsent sein. Sean Brynjelsen, CEO, und James Gruber, CFO, werden teilnehmen. Für Meetinganfragen kontaktieren Sie bitte Citizens JMP.
Positive
None.
Negative
None.
DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelsen, Chief Executive Officer, and James Gruber, Chief Financial Officer, will present at the Citizens JMP Life Sciences Conference in New York as follows:
To schedule a 1x1 meeting with the Company, please contact your Citizens JMP institutional sales representative.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has five commercial rare disease products: ALKINDI SPRINKLE®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Investor Relations: Lisa M. Wilson, In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com
Source: Eton Pharmaceuticals.
FAQ
When will Eton Pharmaceuticals present at the Citizens JMP Life Sciences Conference?
Eton Pharmaceuticals will present on May 13, 2024.
Who will be representing Eton Pharmaceuticals at the conference?
Sean Brynjelsen, CEO, and James Gruber, CFO, will be presenting.
Where will the Citizens JMP Life Sciences Conference take place?
The conference will be held in New York.
How can one schedule a meeting with Eton Pharmaceuticals during the conference?
To schedule a meeting, contact your Citizens JMP institutional sales representative.
eton pharmaceuticals, inc. is a deer park, illinois-based pharmaceutical company focused on developing and commercializing innovative pharmaceutical products utilizing the u.s. food and drug administration’s 505(b)(2) regulatory pathway. our mission is to advance healthcare through the introduction of innovative medicines that are affordable and available to all patients.
